Black Diamond Therapeutics Inc (BDTX NASDAQ) stock market data APIs
$2.4828
-0.13(-5.2%)
as of June 30, 2025
Try our APIs with
free plan!
Black Diamond Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Prev. Close
2.4828
Open
2.354
High
2.4828
Low
2.354
52 wk Range
1.195-6.75
Market Cap
141 M
P/E Ratio
41.3333
Shares Outstanding
56 863 K
Revenue
70 000 K
EPS
0.98
Beta
2.712
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Black Diamond Therapeutics Inc data using free add-ons & libraries
Get Black Diamond Therapeutics Inc Fundamental Data
Black Diamond Therapeutics Inc Fundamental data includes:
- Net Revenue: 70 000 K
- EBITDA: -716 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.255
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Black Diamond Therapeutics Inc News
New
ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data
Investing.com - H.C. Wainwright has reiterated a Buy rating and $40.00 price target on ArriVent BioPharma (NASDAQ:AVBP) following updated results from the company’s Phase 1b FURTHER trial evaluating...
Veru And Two Other Penny Stocks To Consider
Over the last 7 days, the United States market has risen by 1.7%, and over the past year, it is up 12%, with earnings forecasted to grow by 15% annually. For investors seeking opportunities beyond wel...
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma pa...
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with b...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
